title: Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
abstract: Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.
authors.affiliation: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, USA.
authors.forename: V E
authors.initials: VE
authors.lastname: Anderson
authors.forename: R P
authors.initials: RP
authors.lastname: Zaniewski
authors.forename: F S
authors.initials: FS
authors.lastname: Kaczmarek
authors.forename: T D
authors.initials: TD
authors.lastname: Gootz
authors.forename: N
authors.initials: N
authors.lastname: Osheroff
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology; D005075:Biological Evolution; D002939:Ciprofloxacin / Q000494:pharmacology*; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D004926:Escherichia coli / Q000201:enzymology; D005047:Etoposide / Q000494:pharmacology; D024841:Fluoroquinolones; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007700:Kinetics; D015363:Quinolones / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000201:enzymology* / Q000235:genetics
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C070116:CP 115953; D002939:Ciprofloxacin; D005047:Etoposide; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II